Objective: The erythrocyte indices (mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and mean corpuscular hemoglobin (MCH)) were originally reported using handcalculated values, based on a centrifuge-spun hematocrit, a countingchamber erythrocyte count and a hemoglobin concentration measured by any number of hemoglobinometry methods. Modern blood cell analyzers measure the MCV, and calculate the MCHC and MCH, on the basis of logs higher sample sizes than employed in the original methods.
Introduction
The erythrocyte indices were among the discoveries and innovations in clinical hematology made by Dr Maxwell M Wintrobe. 1 The indices were intended to provide estimates of the average size of circulating eythrocytes (mean corpuscular volume, MCV), the average concentration of hemoglobin per erythrocyte (mean corpuscular hemoglobin concentration, MCHC) and the average quantity of hemoglobin within erythrocytes (mean corpuscular hemoglobin, MCH).
For many decades the erythrocyte indices were hand calculated after quantifying the hemoglobin concentration, the hematocrit and the erythrocyte concentration. [2] [3] [4] [5] [6] [7] Modern laboratory hematology analyzers now use direct measurements and electronic calculations to generate the erythrocyte indices, and they do so utilizing logs higher sample sizes than the original methods. 8 For instance the Beckman Coulter LH 750 hematology analyzer uses a combination of cell volume, measured by direct current, cell conductivity analysis, using radio frequency measurements to provide information about the internal characteristics of the cells, and cell light scatter, using a helium-neon laser beam. 8 Little has been published, using any method, on the expected range of erythrocyte indices among extremely low birth weight neonates (<1000 g), which now populate most level III neonatal intensive care units (NICUs). Therefore, we sought to describe the normal range of erythrocyte indices of neonates ranging from 22 to 42 weeks gestation on the first day of life, using modern instrumentation, by utilizing the database from an 18-hospital system in the western United States.
Methods
Information was collected as a deidentified limited data set from archived Intermountain Healthcare records. The information collected was limited to that displayed in the figures of this report. Erythrocyte indices were analyzed from patients with a date of birth from 1 January 2004 through 31 December 2006. The tests analyzed were those obtained within the first 24 h after delivery, among patients who had not received an erythrocyte transfusion, and only if the blood sample had been run on a Beckman Coulter LH 750, which is the instrument present in all Intermountain Healthcare Hospitals that have a level III NICU. 4 Gestational age was determined by obstetrical assignment unless this was changed by the neonatal examination.
The program used for data collection was a modified subsystem of 'clinical workstation'. Clinical workstation is a Web-based electronic medical record application that stores demographic and clinical information, such as history, physical examination results, laboratory data, problem lists and discharge summaries. 3M Company (Minneapolis, MN, USA) approved the structure and definitions of all data points for use within the program. The data were collected from the electronic medical record, laboratory systems and case mix. Case mix is the billing, coding and financial data mart used by Intermountain Healthcare. Data were managed and accessed by authorized data analysts. Descriptive statistics were calculated using Statit (Corvallis, OR, USA). Means and standard deviations, and 95% confidence intervals were used to express the data. The Intermountain Healthcare Institutional Review Board approved the study.
Results
Erythrocyte indices were included from 17 624 samples obtained on 12 016 untransfused neonates, with gestational ages ranging from 22 to 42 weeks. The exact number of patients at each gestational age contributing data to the analysis is shown in Figure 1 . All values obtained were included in the analysis. Over this span of gestational ages, the MCV and the MCH decreased with advancing gestational age ( Figure 2 ). For instance, the MCV diminished from 119 ± 7 fl (mean ± s.d.) in neonates p25 weeks gestation, to 116±6 fl in those at 28 weeks gestation, to 109±5 fl at 34 weeks gestation and to 106 ± 4 fl at 40 weeks. Similarly, the MCH diminished from 40 ± 2 pg in neonates p25 weeks gestation to 36±2 pg at 40 weeks. The MCHC did not change appreciably with gestational age (34 ± 1 pg dl À1 ). A smoothed figure, illustrating the 95% confidence intervals of expected MCV and MCH values, is shown in Figure 3 .
Discussion
The MCV is a measure of the average size of circulating erythrocytes. Modern automated cell counters use laser optics or aperture-impedance technology to directly measure the MCV, sampling millions of erythrocytes to do so. 4 However, the MCV as originally described was hand calculated 1-3,5 after a spun hematocrit and a dilution chamber erythrocyte count, using the formula:
Erythrocyte count ðÂ10 12 l À1 Þ
The MCHC is a measure of the concentration of hemoglobin in an average circulating erythrocyte. The MCHC is a calculated value in modern automated cell counters, using a measured value for hemoglobin and a calculated value for the hematocrit, using the formula:
The MCH is a measure of the average amount of hemoglobin in circulating erythrocytes. Modern cell counters calculate the MCH after measuring the hemoglobin concentration and measuring the concentration of erythrocytes using laser optics or apertureimpedance technology. 4 The formula for the MCH is:
MCH Our present project sought to expand the previous reports, by compiling a very large number of measurements of erythrocyte indices, over a wide range of gestational ages, using a single model of automated blood cell counter, within one health care system. We recognize, as shown in Figure 1 , that the great majority of values we report were derived from neonates of highest gestation, with fewer than 400 patients <28 weeks represented. Because of the potentially confounding effects of erythrocyte transfusions and postnatal age on the erythrocyte indices, we limited our study to values obtained in the first 24 h of life among neonates who had never been transfused (either intrauterine or postnatal). We confirmed that erythrocytes are very large in neonates at the limits of extrauterine viability, and that erythrocyte size falls steadily as gestational age advances. Even at term, the MCV is strikingly higher than the upper limit of normal among healthy adults. [1] [2] [3] We assume these very large erythrocytes are advantageous to the fetus, although it is not clear what those advantages are. Perhaps the very high content of hemoglobin carried by these large cells somehow constitutes an advantage to the fetus. Whether large erythrocytes are also advantageous for prematurely delivered neonates ex utero is not known. Many preterm neonates have large phlebotomy losses in the first week of NICU care and are transfused with much smaller erythrocytes from adult donors. The consequences of this change in erythrocyte size are not known.
In general, reticulocytes have a higher MCV than do nonreticulocyte erythrocytes, and the reticulocyte count in a normal fetus is four to eight times higher than in health adults. 5, 11 However, this difference is not sufficient to explain the higher MCV of the fetus, because the nonreticulocyte erythrocytes of a fetus are also considerably larger than those of adults. 12 In adults, an MCV and MCH elevated to the range observed in the normal midtrimester fetus (122 fl and 40 pg) can suggest folate or vitamin B 12 deficiency, or abnormal metabolism of folate or B 12 . 13 However, the high MCV and MCH of the fetus are not otherwise analogous to folate or B 12 deficiency, in that the normal fetus has no other aspects of megaloblastic anemia, and is not anemic but is relatively polycythemic by adult standards. 5 A small MCV and MCH can be an indicator of iron deficiency or a-thalassemia.
14 Meloni et al. 15 utilized a Hemalog 8/90 electronic cell counter to determine the erythrocyte indices of term neonates with a-thalassemia, comparing these with normal term neonates. They found that the MCV and MCH were generally lower among neonates with a-thalassemia, but that such determinations were not sufficiently reliable to be used as a sensitive screening method. 16 Perhaps using erythrocyte indices along with ethnic background and analysis of a peripheral blood smear looking in particular for target cells can be useful for differentiating three to four gene deletion a-thalassemia from iron deficiency or other conditions.
In our patients, the MCHC did not change significantly during gestation. We found it curious that the MCHC of our patients was about 1 g dl À1 higher than that reported in African 17, 9 neonates, and the MCH of our patients was about 4 pg higher. 10 Whether these differences reflect greater iron sufficiency among mothers in the western United States, or is due to a higher carrier state for thalassemia among the African neonates or is due to another explanation is unclear. A high MCHC can be an indication that the erythrocytes are spherical, or have a shape intermediate between a sphere and a biconcave disk. This is because, given a uniform surface area, a sphere can hold more volume than can a biconcave disk. 15 Thus, conditions characterized by spherocytic erythrocytes are likely to have a high MCHC. In the neonatal period the most common cause of spherocytosis is ABO hemolytic jaundice, but it is not clear whether a high MCHC can be used to identify these patients during the first days of life.
The anatomical site of erythropoiesis changes during fetal development, and these changes may be involved in the progressive fall in erythrocyte size and erythrocyte hemoglobin concentration we observed. For instance, definitive erythrocytes, initially large and nucleated, first appear in the yolk sac and near the dorsal aorta of the embryo, in the region called the aorta-gonad-mesonephros. Erythropoiesis then moves to the liver and finally to the bone marrow. [18] [19] [20] We speculate that during this process, the larger erythrocytes, laden with more hemoglobin that is more avid for oxygen, provide the fetus with a better ability to move oxygen from the maternal to the fetal circulation.
Additional studies are needed regarding patients with very high or very low erythrocyte indices that fall outside the limits we report in this study. We maintain that the present report is a useful step in that process, because now we have a better definition of the expected red blood cell values, at various gestational ages, so that neonates with values higher or lower than expected can be flagged for further evaluation. More study is also needed to determine any advantage that these very large, hemoglobin-laden erythrocytes have for the fetus or for the prematurely born neonate. We maintain that recognizing the developmental changes in erythrocyte indices can be of value in such studies.
